Home LiteratureArticle Details
PMID: 3127028 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article

Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 alpha-hydroxylase reserve in postmenopausal osteoporosis.

Calcified tissue international ·Vol. 42 ·No. 2 ·1988-02-00 ·Pages 77-86

Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C

Abstract

A double-blind, placebo-controlled study on 21 postmenopausal osteoporotic women was performed in order to assess the effects of 1 year estrogen therapy (Premarin, 1.25 mg/day) on bone mass, intestinal calcium absorption, and mineral metabolism. Bone mineral content (BMC), measured by dual photon absorptiometry on the vertebral bodies and the femoral shaft, increased in both areas, but the changes were more evident at the former site, which is predominantly trabecular (+8.3%, P less than 0.05), than at the latter, which is mainly cortical (+2.6%, P less than 0.05). An improvement of intestinal calcium absorption was also detected at the end of the study (P less than 0.05) in the estrogen-treated group. Parameters of bone metabolism showed a decrease in hydroxyproline/creatinine ratio and osteocalcin, an increase in calcitonin, and no significant changes in parathyroid hormone (PTH) and alkaline phosphatase. Serum 1,25-dihydroxycholecalciferol (1,25(OH)2D3) levels increased after estrogen therapy, whereas 25-hydroxycholecalciferol (25OHD3) remained stable during the study period. Renal 25-hydroxyvitamin D 1 alpha-hydroxylase reserve, assessed by the PTH-stimulation test, showed a more rapid response in producing a 1,25(OH)2D3 peak in the estrogen-treated patients compared with the control subjects. However, estrogens did not induce an absolute improvement in the secretory reserve. This study demonstrates that 1 year treatment with estrogens improves both intestinal calcium absorption and BMC in postmenopausal osteoporotic women. The latter effect appears to be induced by an inhibition of bone resorption, associated to an increased secretion of calcitonin, whereas vitamin D metabolites do not seem to contribute substantially to the mediation of estrogen action on bone.

MeSH Terms
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism Bone and Bones/drug effects Calcitonin/analysis Calcium/metabolism Estrogens/administration & dosage,pharmacology,therapeutic use Female Femur/analysis Humans Intestinal Absorption/drug effects Kidney/analysis,enzymology Lumbar Vertebrae/analysis Osteoporosis/drug therapy Parathyroid Hormone/analysis Radioimmunoassay Radionuclide Imaging Steroid Hydroxylases/metabolism
Chemicals
Estrogens Parathyroid Hormone Calcitonin Steroid Hydroxylases 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Calcium
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Civitelli R
Division of Bone and Mineral Metabolism, Jewish Hospital of St. Louis, Washington University Medical Center, Missouri.
Agnusdei D
Nardi P
Zacchei F
Avioli L V
Gennari C
References (65)
65 references, click to expand
  1. The minimum effective dose of estrogen for prevention of postmenopausal bone loss.
    Obstet Gynecol. 1984 Jun;63(6):759-63 PMID: 6374537
  2. Calcium-regulating hormones across the menstrual cycle.
    J Clin Endocrinol Metab. 1986 Jun;62(6):1313-6 PMID: 3084541
  3. Decreased calcitonin reserve in accelerated postmenopausal osteoporosis.
    Horm Metab Res. 1985 Dec;17(12):696-7 PMID: 4085976
  4. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease.
    J Clin Invest. 1984 Dec;74(6):1966-71 PMID: 6549014
  5. Oophorectomy leads to a selective decrease in 1,25-dihydroxycholecalciferol receptors in rat jejunal villous cells.
    Clin Sci (Lond). 1984 Jun;66(6):745-8 PMID: 6327143
  6. Menopausal changes in bone remodeling.
    J Lab Clin Med. 1978 Dec;92(6):964-70 PMID: 739174
  7. Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens.
    Lancet. 1981 Mar 28;1(8222):693-5 PMID: 6110915
  8. Calcium malabsorption in elderly women with vertebral fractures: evidence for resistance to the action of vitamin D metabolites on the bowel.
    Clin Sci (Lond). 1984 Jan;66(1):103-7 PMID: 6606522
  9. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.
    N Engl J Med. 1984 Nov 15;311(20):1273-5 PMID: 6493283
  10. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women.
    Br Med J. 1973 May 12;2(5862):325-8 PMID: 4704517
  11. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis?
    Lancet. 1982 Feb 27;1(8270):475-8 PMID: 6121141
  12. A test of 1,25-dihydroxyvitamin D3 secretory capacity in normal subjects for application in metabolic bone diseases.
    Clin Endocrinol (Oxf). 1983 Feb;18(2):127-33 PMID: 6687845
  13. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.
    Eur J Clin Invest. 1980 Aug;10(4):273-9 PMID: 6253303
  14. Menopausal changes in calcium balance performance.
    J Lab Clin Med. 1978 Dec;92(6):953-63 PMID: 739173
  15. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.
    Obstet Gynecol. 1979 Mar;53(3):277-81 PMID: 218151
  16. Deficiency of calcitonin in age related osteoporoses.
    Biomedicine. 1978 Nov;29(8):272-6 PMID: 556387
  17. Synergistic effect of progesterone, testosterone, and estradiol in the stimulation of chick renal 25-hydroxyvitamin D3-1alpha-hydroxylase.
    Endocrinology. 1978 Dec;103(6):2035-9 PMID: 748032
  18. Effects of a short course of estrogen on mineral metabolism in postmenopausal women.
    J Clin Endocrinol Metab. 1985 Oct;61(4):595-600 PMID: 2993339
  19. Effects of estradiol and progesterone on calcitonin secretion.
    Endocrinology. 1986 Jun;118(6):2594-8 PMID: 3698924
  20. The effect of oestrogens on human calcitonin secretion after calcium infusion in elderly female subjects.
    Clin Endocrinol (Oxf). 1980 Aug;13(2):135-43 PMID: 7438468
  21. The role of sex hormones and synthetic steroids in prevention of post-menopausal osteoporosis.
    Clin Invest Med. 1982;5(2-3):189-94 PMID: 7116726
  22. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis.
    J Clin Invest. 1972 Jul;51(7):1659-63 PMID: 4338118
  23. Non-linear bone loss in oophorectomized women.
    Br J Radiol. 1977 Jul;50(595):504-7 PMID: 871602
  24. Influence of estrogen on renal vitamin D hydroxylases and serum 1alpha,25-(OH)2D3 in chicks.
    Am J Physiol. 1978 Sep;235(3):E338-43 PMID: 211856
  25. Interrelations of calcium-regulating hormones during normal pregnancy.
    Br Med J (Clin Res Ed). 1981 Jul 4;283(6283):10-2 PMID: 6788241
  26. Histological studies of bone from normocalcemic post-menopausal osteoporotic patients with increased circulating parathyroid hormone.
    J Clin Endocrinol Metab. 1976 Mar;42(3):537-43 PMID: 1254694
  27. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.
    Lancet. 1976 May 15;1(7968):1038-41 PMID: 57448
  28. Estrogen receptors in bone. An evaluation of the uptake of estrogen into bone cells.
    Proc Soc Exp Biol Med. 1974 May;146(1):265-8 PMID: 4363826
  29. Estrogen and progestin effects on urinary calcium and calciotropic hormones in surgically-induced postmenopausal women.
    Horm Metab Res. 1985 Jul;17(7):370-3 PMID: 3161813
  30. A syndrome of osteoporosis, increased serum immunoreactive parathyroid hormone, and inappropriately low serum 1,25-dihydroxyvitamin D.
    Mayo Clin Proc. 1978 Nov;53(11):701-6 PMID: 713601
  31. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation.
    J Clin Invest. 1979 Feb;63(2):342-4 PMID: 429557
  32. Calcitonin and postmenopausal osteoporosis.
    Clin Endocrinol (Oxf). 1984 Jan;20(1):85-92 PMID: 6362926
  33. The effect of estrogen dose on postmenopausal bone loss.
    N Engl J Med. 1983 Dec 8;309(23 ):1405-7 PMID: 6633616
  34. Serum calcium regulating hormones in the perinatal period.
    Calcif Tissue Int. 1982 Mar;34(2):131-5 PMID: 6805918
  35. Effects in postmenopausal women of natural and synthetic estrogens on calcitonin and calcium-regulating hormone secretion. Relevance to postmenopausal osteoporosis.
    Acta Obstet Gynecol Scand Suppl. 1981;106:27-32 PMID: 6951874
  36. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy.
    Ann Intern Med. 1982 Nov;97(5):699-705 PMID: 6291439
  37. Calcitonin secretion in postmenopausal osteoporosis.
    N Engl J Med. 1985 Apr 25;312(17):1097-100 PMID: 3982469
  38. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.
    J Clin Invest. 1980 Nov;66(5):878-83 PMID: 6968755
  39. A prospective study of change in bone mass with age in postmenopausal women.
    J Chronic Dis. 1982;35(9):715-25 PMID: 7107805
  40. Interaction between parathyroid hormone and endogenous estrogen in normal women.
    Metabolism. 1986 Jun;35(6):489-94 PMID: 3754923
  41. Intestinal absorption of calcium-47 after treatment with oral oestrogen-gestogens in senile osteoporosis.
    Br Med J. 1970 Oct 3;4(5726):30-2 PMID: 5470432
  42. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study.
    Lancet. 1979 Oct 6;2(8145):705-9 PMID: 90802
  43. Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones.
    Clin Sci (Lond). 1985 Sep;69(3):265-71 PMID: 3933891
  44. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis.
    J Clin Invest. 1981 Feb;67(2):328-35 PMID: 7462421
  45. Kinetic analysis of plasma radioactivity after oral ingestion of radiocalcium.
    Nature. 1969 May 24;222(5195):797 PMID: 5786201
  46. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss.
    Am J Obstet Gynecol. 1987 Jan;156(1):61-5 PMID: 3541622
  47. Effect of estrogen on vitamin D metabolism in tall girls.
    J Clin Endocrinol Metab. 1983 Dec;57(6):1155-8 PMID: 6605356
  48. Menopausal estrogen therapy and hip fractures.
    Ann Intern Med. 1981 Jul;95(1):28-31 PMID: 7247123
  49. Prevention of spinal osteoporosis in oophorectomised women.
    Lancet. 1980 Nov 29;2(8205):1151-4 PMID: 6107766
  50. Prospective trial of oestrogen and calcium in postmenopausal women.
    Br Med J. 1977 Sep 24;2(6090):789-92 PMID: 912324
  51. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 1980 Dec;51(6):1359-64 PMID: 6255005
  52. Serum 1,25-dihydroxyvitamin D in normal subjects and in patients with postmenopausal osteopenia. Influence of age, renal function and oestrogen therapy.
    Horm Metab Res. 1982 May;14(5):271-4 PMID: 6896507
  53. Preventive effect of estrogen on postmenopausal bone loss.
    Arch Intern Med. 1975 Nov;135(11):1436-40 PMID: 1190928
  54. Influence of pregnancy on immunoreactive parathyroid hormone levels.
    Calcif Tissue Int. 1982 Jan;34(1):9-12 PMID: 6279256
  55. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women.
    Ann Intern Med. 1977 Dec;87(6):649-55 PMID: 201203
  56. Distinction between alpha-fetoprotein and intracellular estrogen receptors: evidence against the presence of estradiol receptors in rat bone.
    Endocrinology. 1978 Jan;102(1):236-44 PMID: 217584
  57. The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women.
    J Lab Clin Med. 1980 Mar;95(3):373-85 PMID: 7354241
  58. Risk factors for postmenopausal osteoporosis.
    Am J Med. 1985 Jan;78(1):95-100 PMID: 3966495
  59. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration.
    J Clin Invest. 1981 Mar;67(3):589-96 PMID: 6894152
  60. Serum bone Gla protein variations during estrogen and calcium prophylaxis of postmenopausal women.
    Calcif Tissue Int. 1984 Sep;36(5):536-40 PMID: 6441624
  61. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium.
    Ann Intern Med. 1987 Jan;106(1):40-5 PMID: 3789576
  62. Assessment of 25-hydroxyvitamin D 1 alpha-hydroxylase reserve in postmenopausal osteoporosis by administration of parathyroid extract.
    J Clin Endocrinol Metab. 1981 Oct;53(4):833-5 PMID: 7287865
  63. Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 1985 Sep;61(3):457-61 PMID: 3926808
  64. Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis.
    Metabolism. 1980 Jun;29(6):559-62 PMID: 7382823
  65. A specific method for the analysis of hydroxyproline in tissues and urine.
    Anal Biochem. 1960 Nov;1:228-39 PMID: 13738134
Article Info
Journal
Calcified tissue international
Abbr.
Calcif Tissue Int
ISSN
0171-967X
DOI
10.1007/BF02556338
Published
1988-02-00
Pages
77-86
Language
English
Region
United States
NLM ID
7905481
Subset
IM
External Links
PubMed source DOI: 10.1007/BF02556338 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2